Tandem Diabetes Care (TNDM) 7.06 $TNDM Tandem D
Post# of 273258
Posted On: 09/02/2016 7:10:16 AM
Tandem Diabetes Care (TNDM) 7.06 $TNDM
Tandem Diabetes Care Announces Upcoming Conference Presentations
BusinessWire - Wed Aug 24, 3:04PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the following upcoming investor conferences:
TNDM: 7.06 (-0.07)
Tandem Diabetes Care to Present at the 2016 Wedbush PacGrow Healthcare Conference
BusinessWire - Thu Aug 04, 3:06PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the 2016 Wedbush PacGrow Healthcare Conference in New York, NY. The presentation will take place on Tuesday, August 16, 2016 at 1:55 PM Eastern Time (10:55 AM Pacific Time).
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Reports Second Quarter 2016 Financial Results, Updates 2016 Guidance and Announces New t:slim X2(TM) Insulin Pump and Associated Technology Upgrade Program
BusinessWire - Thu Jul 28, 3:05PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today reported its financial results for the quarter ended June 30, 2016 and updated its financial guidance for the year ending December 31, 2016. The Company also announced the development of a next generation pump platform, the t:slim X2(TM) Insulin Pump, which the Company is planning to launch in the fourth quarter of 2016. With today's announcement, the Company will begin to offer eligible t:slim(R) and t:slim G4(TM) Insulin Pump customers a Technology Upgrade Program to provide a pathway to the new t:slim X2 Pump when it becomes available.
TNDM: 7.06 (-0.07)
Commit To Purchase Tandem Diabetes Care At $5, Earn 6% Annualized Using Options
StockOptionsChannel.com - Fri Jun 17, 10:41AM CDT
Investors considering a purchase of Tandem Diabetes Care Inc shares, but cautious about paying the going market price of $7.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
TNDM: 7.06 (-0.07)
Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue May 03, 3:50PM CDT
PHOTO CREDIT: INSULET. What: Shares of Insulet Corporation and Tandem Diabetes Care , both medical-device companies primarily focused on creating products that help treat diabetes, plunged by double digits today after Tandem released some...
PODD: 42.46 (+0.13), TNDM: 7.06 (-0.07)
Tandem Diabetes Care Announces Upcoming Change to UnitedHealthcare Customer Access
BusinessWire - Tue May 03, 8:00AM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, stated that it has learned that UnitedHealthcare yesterday announced that effective July 1, 2016, UnitedHealthcare Community Plan and Commercial members will no longer have an in-network choice among insulin pump providers. This unexpected decision by UnitedHealthcare designates Medtronic as their preferred, in-network durable medical equipment provider of insulin pumps. The Company anticipates that this decision will prevent a majority of UnitedHealthcare members from purchasing an insulin pump on an in-network basis from Tandem Diabetes Care and several other durable medical equipment providers.
MDT: 86.98 (-0.05), TNDM: 7.06 (-0.07)
Tandem Diabetes reports 1Q loss
Automated Insights - Thu Apr 28, 5:27PM CDT
SAN DIEGO (AP) _ Tandem Diabetes Care Inc. (TNDM) on Thursday reported a loss of $20.5 million in its first quarter.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Reports First Quarter 2016 Financial Results and Updates 2016 Guidance
BusinessWire - Thu Apr 28, 3:20PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today reported its financial results for the quarter ended March 31, 2016 and updated its financial guidance for the year ending December 31, 2016.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care to Present at the Deutsche Bank 41st Annual Health Care Conference
BusinessWire - Wed Apr 27, 3:15PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Deutsche Bank 41st Annual Health Care Conference in Boston, MA. The presentation will take place on Wednesday, May 4, 2016 at 9:20 AM Eastern Time (6:20 AM Pacific Time).
TNDM: 7.06 (-0.07), DB: 14.69 (-0.06)
Tandem Diabetes Care Schedules First Quarter 2016 Earnings Press Release and Conference Call
BusinessWire - Thu Apr 14, 3:04PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, plans to release its first quarter 2016 results after the markets close on Thursday, April 28, 2016. The Company will hold a conference call and simultaneous webcast on the same day at 5:30 PM Eastern Time (2:30 PM Pacific Time), to discuss its first quarter 2016 financial and operating results.
TNDM: 7.06 (-0.07)
Dr. Henry Anhalt to Step Down From Tandem Diabetes Care Board of Directors to Ensure No Risk of Potential Conflict of Interest
BusinessWire - Fri Apr 08, 3:15PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Henry Anhalt, DO, FACOP, FACE has stepped down from its board of directors. Dr. Anhalt is chief medical officer of T1D Exchange, a program of the nonprofit organization Unitio, that fosters collaboration among patients, physicians, researchers and industry to speed discovery of better therapies for type 1 diabetes. Prior to his appointment in March 2016, Dr. Anhalt had the support of T1D Exchange to serve on Tandem's Board. The non-profit's governing body had conducted a thorough review of any risk of potential for conflict of interest. Following the announcement of Dr. Anhalt's appointment to Tandem's Board, T1D Exchange received member concerns about potential conflicts of interest, and as a result, Dr. Anhalt has notified Tandem that he regrettably is no longer able to serve on its board of directors.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Schedules Fourth Quarter and Full Year 2015 Earnings Press Release and Conference Call
BusinessWire - Wed Feb 10, 3:34PM CST
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:flex(R) and t:slim G4(TM) Insulin Pumps, plans to release its fourth quarter and full year 2015 results after the financial markets close on Wednesday, February 24, 2016. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its fourth quarter and full year 2015 financial and operating results.
TNDM: 7.06 (-0.07)
Downtrend Call Working As Neutral Tandem Stock Falls 29.0% (TNDM)
Comtex SmarTrend(R) - Tue Feb 09, 6:09PM CST
SmarTrend identified a Downtrend for Neutral Tandem (NASDAQ:TNDM) on January 11th, 2016 at $10.06. In approximately 4 weeks, Neutral Tandem has returned 29.04% as of today's recent price of $7.14.
TNDM: 7.06 (-0.07)
Neutral Tandem Shares Down 21.0% Since SmarTrend's Sell Call (TNDM)
Comtex SmarTrend(R) - Tue Feb 02, 3:26PM CST
SmarTrend identified a Downtrend for Neutral Tandem (NASDAQ:TNDM) on January 11th, 2016 at $10.06. In approximately 3 weeks, Neutral Tandem has returned 21.03% as of today's recent price of $7.94.
TNDM: 7.06 (-0.07)
Shares of TNDM Down 21.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 02, 2:15PM CST
SmarTrend identified a Downtrend for Neutral Tandem (NASDAQ:TNDM) on January 11th, 2016 at $10.06. In approximately 3 weeks, Neutral Tandem has returned 21.03% as of today's recent price of $7.94.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Expands Commercial Leadership
BusinessWire - Tue Feb 02, 7:30AM CST
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Brian Hansen has joined the Company as Executive Vice President and Chief Commercial Officer, and Lori Gildea as Vice President, Sales. Mr. Hansen is responsible for managing the strategic direction of the commercial organization with an emphasis on customer satisfaction, and functional responsibility for sales, marketing and customer service. Ms. Gildea is leading the Company's sales and sales support efforts, which focus on offering a portfolio of insulin pumps to meet the diverse needs of the diabetes community.
TNDM: 7.06 (-0.07)
Downgrade Alert for Neutral Tandem (TNDM)
Comtex SmarTrend(R) - Fri Jan 15, 7:12AM CST
Neutral Tandem (NASDAQ:TNDM) was downgraded from Buy to Neutral at BofA/Merrill today. The stock closed yesterday at $8.05 on volume of 368,000 shares, above average daily volume of 181,000. Neutral Tandem (NASDAQ:TNDM) has potential upside of 104.6% based on a current price of $8.05 and analysts' consensus price target of $16.47. The stock should find initial resistance at its 50-day moving average (MA) of $10.74 and further resistance at its 200-day MA of $11.27.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Amends Term Loan Facility with CRG
BusinessWire - Tue Jan 12, 8:00AM CST
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM) today announced the amendment of its term loan facility with Capital Royalty Partners II, L.P. and its affiliate funds ("CRG"
, which will provide the Company access to $50 million in addition to the $30 million borrowed from CRG in January 2013. Under the terms of the amended agreement, Tandem is required to draw $15 million in January 2016 and has a one-time option to access up to an additional $35 million on or before December 31, 2016. The interest rate, interest only payment period, and maturity date under the loan facility were unchanged by the amendment.
TNDM: 7.06 (-0.07)
12.7% Return Seen to Date on SmarTrend Neutral Tandem Call (TNDM)
Comtex SmarTrend(R) - Mon Jan 11, 6:48PM CST
SmarTrend identified an Uptrend for Neutral Tandem (NASDAQ:TNDM) on October 30th, 2015 at $8.78. In approximately 2 months, Neutral Tandem has returned 12.71% as of today's recent price of $9.89.
TNDM: 7.06 (-0.07)
Neutral Tandem Has Returned 34.7% Since SmarTrend Recommendation (TNDM)
Comtex SmarTrend(R) - Mon Dec 28, 9:55AM CST
SmarTrend identified an Uptrend for Neutral Tandem (NASDAQ:TNDM) on October 30th, 2015 at $8.78. In approximately 2 months, Neutral Tandem has returned 34.70% as of today's recent price of $11.82.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Announces Upcoming Conference Presentations
BusinessWire - Wed Aug 24, 3:04PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the following upcoming investor conferences:
TNDM: 7.06 (-0.07)
Tandem Diabetes Care to Present at the 2016 Wedbush PacGrow Healthcare Conference
BusinessWire - Thu Aug 04, 3:06PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the 2016 Wedbush PacGrow Healthcare Conference in New York, NY. The presentation will take place on Tuesday, August 16, 2016 at 1:55 PM Eastern Time (10:55 AM Pacific Time).
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Reports Second Quarter 2016 Financial Results, Updates 2016 Guidance and Announces New t:slim X2(TM) Insulin Pump and Associated Technology Upgrade Program
BusinessWire - Thu Jul 28, 3:05PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today reported its financial results for the quarter ended June 30, 2016 and updated its financial guidance for the year ending December 31, 2016. The Company also announced the development of a next generation pump platform, the t:slim X2(TM) Insulin Pump, which the Company is planning to launch in the fourth quarter of 2016. With today's announcement, the Company will begin to offer eligible t:slim(R) and t:slim G4(TM) Insulin Pump customers a Technology Upgrade Program to provide a pathway to the new t:slim X2 Pump when it becomes available.
TNDM: 7.06 (-0.07)
Commit To Purchase Tandem Diabetes Care At $5, Earn 6% Annualized Using Options
StockOptionsChannel.com - Fri Jun 17, 10:41AM CDT
Investors considering a purchase of Tandem Diabetes Care Inc shares, but cautious about paying the going market price of $7.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
TNDM: 7.06 (-0.07)
Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue May 03, 3:50PM CDT
PHOTO CREDIT: INSULET. What: Shares of Insulet Corporation and Tandem Diabetes Care , both medical-device companies primarily focused on creating products that help treat diabetes, plunged by double digits today after Tandem released some...
PODD: 42.46 (+0.13), TNDM: 7.06 (-0.07)
Tandem Diabetes Care Announces Upcoming Change to UnitedHealthcare Customer Access
BusinessWire - Tue May 03, 8:00AM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, stated that it has learned that UnitedHealthcare yesterday announced that effective July 1, 2016, UnitedHealthcare Community Plan and Commercial members will no longer have an in-network choice among insulin pump providers. This unexpected decision by UnitedHealthcare designates Medtronic as their preferred, in-network durable medical equipment provider of insulin pumps. The Company anticipates that this decision will prevent a majority of UnitedHealthcare members from purchasing an insulin pump on an in-network basis from Tandem Diabetes Care and several other durable medical equipment providers.
MDT: 86.98 (-0.05), TNDM: 7.06 (-0.07)
Tandem Diabetes reports 1Q loss
Automated Insights - Thu Apr 28, 5:27PM CDT
SAN DIEGO (AP) _ Tandem Diabetes Care Inc. (TNDM) on Thursday reported a loss of $20.5 million in its first quarter.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Reports First Quarter 2016 Financial Results and Updates 2016 Guidance
BusinessWire - Thu Apr 28, 3:20PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today reported its financial results for the quarter ended March 31, 2016 and updated its financial guidance for the year ending December 31, 2016.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care to Present at the Deutsche Bank 41st Annual Health Care Conference
BusinessWire - Wed Apr 27, 3:15PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Deutsche Bank 41st Annual Health Care Conference in Boston, MA. The presentation will take place on Wednesday, May 4, 2016 at 9:20 AM Eastern Time (6:20 AM Pacific Time).
TNDM: 7.06 (-0.07), DB: 14.69 (-0.06)
Tandem Diabetes Care Schedules First Quarter 2016 Earnings Press Release and Conference Call
BusinessWire - Thu Apr 14, 3:04PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, plans to release its first quarter 2016 results after the markets close on Thursday, April 28, 2016. The Company will hold a conference call and simultaneous webcast on the same day at 5:30 PM Eastern Time (2:30 PM Pacific Time), to discuss its first quarter 2016 financial and operating results.
TNDM: 7.06 (-0.07)
Dr. Henry Anhalt to Step Down From Tandem Diabetes Care Board of Directors to Ensure No Risk of Potential Conflict of Interest
BusinessWire - Fri Apr 08, 3:15PM CDT
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Henry Anhalt, DO, FACOP, FACE has stepped down from its board of directors. Dr. Anhalt is chief medical officer of T1D Exchange, a program of the nonprofit organization Unitio, that fosters collaboration among patients, physicians, researchers and industry to speed discovery of better therapies for type 1 diabetes. Prior to his appointment in March 2016, Dr. Anhalt had the support of T1D Exchange to serve on Tandem's Board. The non-profit's governing body had conducted a thorough review of any risk of potential for conflict of interest. Following the announcement of Dr. Anhalt's appointment to Tandem's Board, T1D Exchange received member concerns about potential conflicts of interest, and as a result, Dr. Anhalt has notified Tandem that he regrettably is no longer able to serve on its board of directors.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Schedules Fourth Quarter and Full Year 2015 Earnings Press Release and Conference Call
BusinessWire - Wed Feb 10, 3:34PM CST
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:flex(R) and t:slim G4(TM) Insulin Pumps, plans to release its fourth quarter and full year 2015 results after the financial markets close on Wednesday, February 24, 2016. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its fourth quarter and full year 2015 financial and operating results.
TNDM: 7.06 (-0.07)
Downtrend Call Working As Neutral Tandem Stock Falls 29.0% (TNDM)
Comtex SmarTrend(R) - Tue Feb 09, 6:09PM CST
SmarTrend identified a Downtrend for Neutral Tandem (NASDAQ:TNDM) on January 11th, 2016 at $10.06. In approximately 4 weeks, Neutral Tandem has returned 29.04% as of today's recent price of $7.14.
TNDM: 7.06 (-0.07)
Neutral Tandem Shares Down 21.0% Since SmarTrend's Sell Call (TNDM)
Comtex SmarTrend(R) - Tue Feb 02, 3:26PM CST
SmarTrend identified a Downtrend for Neutral Tandem (NASDAQ:TNDM) on January 11th, 2016 at $10.06. In approximately 3 weeks, Neutral Tandem has returned 21.03% as of today's recent price of $7.94.
TNDM: 7.06 (-0.07)
Shares of TNDM Down 21.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 02, 2:15PM CST
SmarTrend identified a Downtrend for Neutral Tandem (NASDAQ:TNDM) on January 11th, 2016 at $10.06. In approximately 3 weeks, Neutral Tandem has returned 21.03% as of today's recent price of $7.94.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Expands Commercial Leadership
BusinessWire - Tue Feb 02, 7:30AM CST
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim(R), t:slim G4(TM) and t:flex(R) Insulin Pumps, today announced that Brian Hansen has joined the Company as Executive Vice President and Chief Commercial Officer, and Lori Gildea as Vice President, Sales. Mr. Hansen is responsible for managing the strategic direction of the commercial organization with an emphasis on customer satisfaction, and functional responsibility for sales, marketing and customer service. Ms. Gildea is leading the Company's sales and sales support efforts, which focus on offering a portfolio of insulin pumps to meet the diverse needs of the diabetes community.
TNDM: 7.06 (-0.07)
Downgrade Alert for Neutral Tandem (TNDM)
Comtex SmarTrend(R) - Fri Jan 15, 7:12AM CST
Neutral Tandem (NASDAQ:TNDM) was downgraded from Buy to Neutral at BofA/Merrill today. The stock closed yesterday at $8.05 on volume of 368,000 shares, above average daily volume of 181,000. Neutral Tandem (NASDAQ:TNDM) has potential upside of 104.6% based on a current price of $8.05 and analysts' consensus price target of $16.47. The stock should find initial resistance at its 50-day moving average (MA) of $10.74 and further resistance at its 200-day MA of $11.27.
TNDM: 7.06 (-0.07)
Tandem Diabetes Care Amends Term Loan Facility with CRG
BusinessWire - Tue Jan 12, 8:00AM CST
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM) today announced the amendment of its term loan facility with Capital Royalty Partners II, L.P. and its affiliate funds ("CRG"
, which will provide the Company access to $50 million in addition to the $30 million borrowed from CRG in January 2013. Under the terms of the amended agreement, Tandem is required to draw $15 million in January 2016 and has a one-time option to access up to an additional $35 million on or before December 31, 2016. The interest rate, interest only payment period, and maturity date under the loan facility were unchanged by the amendment. TNDM: 7.06 (-0.07)
12.7% Return Seen to Date on SmarTrend Neutral Tandem Call (TNDM)
Comtex SmarTrend(R) - Mon Jan 11, 6:48PM CST
SmarTrend identified an Uptrend for Neutral Tandem (NASDAQ:TNDM) on October 30th, 2015 at $8.78. In approximately 2 months, Neutral Tandem has returned 12.71% as of today's recent price of $9.89.
TNDM: 7.06 (-0.07)
Neutral Tandem Has Returned 34.7% Since SmarTrend Recommendation (TNDM)
Comtex SmarTrend(R) - Mon Dec 28, 9:55AM CST
SmarTrend identified an Uptrend for Neutral Tandem (NASDAQ:TNDM) on October 30th, 2015 at $8.78. In approximately 2 months, Neutral Tandem has returned 34.70% as of today's recent price of $11.82.
TNDM: 7.06 (-0.07)
(0)
(0)Scroll down for more posts ▼